Human Genome Sciences, Inc. and Lonza entered an agreement for the commercial supply of Benlysta (belimumab), which is currently under regulatory review in the U.S. and EU as a potential treatment for systemic lupus erythematosus (SLE). Benlysta is being developed by HGS and GlaxoSmithKline under a co-development and commercialization agreement initiated in 2006. “Our HGS large-scale manufacturing facility has ample capacity to provide worldwide supply of Benlysta following approval, and for ...